Beam Therapeutics Stock Soars 21% in Three Months: Here's Why

Beam Therapeutics shares have risen about 21% over the past three months, outpacing a broader industry downturn, driven by positive early data from BEAM‑302 in an ongoing phase I/II dose‑escalation study for alpha‑1 antitrypsin deficiency (AATD). BEAM‑302 is a liver‑targeting lipid nanoparticle formulation designed to correct the PiZ mutation, with durable increases in functional AAT, reductions in mutant Z‑AAT and generation of corrected M‑AAT, up to single doses of 75 mg and a favorable safety profile. The company plans accelerated approval based on AAT biomarkers evaluated for more than 12 months and expects to enroll about 50 additional patients for a global cohort in H2 2026. Beyond BEAM‑302, Beam aims to submit a BLA for risto‑cel by the end of 2026, while expanding BEAM‑301, BEAM‑304 and BEAM‑103 programs. The company ended Q1 2026 with about $1.2 billion in cash, cash equivalents and marketable securities, supporting ongoing development without near‑term dilution.